METALINEAR
metaLinear focuses on the identification and validation of new drug targets for difficult to treat bacterial infections. metaLinear uses a proprietary proteome engineering platform technology to uncover, characterise and validate new targets for antibiotics. Using very large libraries of Randomised proteins (R-teins) expressed in target bacteria, metaLinear will screen for novel targets responsible for the desired phenotype. A key advantage of this approach is the ability to de-risk targets and hence provide multiple efficiency gains in the traditional target and drug discovery process.
METALINEAR
Industry:
Biotechnology Health Care Medical
Founded:
2017-01-01
Address:
Alderley Edge, Cheshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.metalinear.co.uk
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
255 K GBP
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail
Similar Organizations
Acthera Therapeutics
Acthera Therapeutics is developing an innovative nanotechnology-based platform for the controlled and targeted drug delivery
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Employees Featured
Founder
Investors List
Catapult Ventures
Catapult Ventures investment in Seed Round - metaLinear
Alderley Park Ventures
Alderley Park Ventures investment in Seed Round - metaLinear
GM&C Life Sciences Fund
GM&C Life Sciences Fund investment in Seed Round - metaLinear
Official Site Inspections
http://www.metalinear.co.uk
- Host name: asset-uk-l5p-server1.assetict.com
- IP address: 198.244.202.235
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
